Pronetics

Our Prostate Cancer Gene Panel


North Central Florida Diagnostics & DNA Technologies (NCF DNA) brings the accessibility of genetic testing to individuals who have an increased risk of inherited prostate cancer. Next Generation Sequencing allows the identification of high-risk individuals and provides a key to an early diagnosis of cancer and proactive care.

Using targeted genomic Next Generation Sequencing, we screen for germ-line mutations in 22 genes identified as conferring high risk for cancer as seen in individual with prostate cancer. This is a sub-panel of our comprehensive panel.

Our Pronetics TM panel consists of the following high-risk cancer genes: ATM, BRCA1, BRCA2, CANCA1D, CHEK2, ELAC2, EPCAM, HNF1A, HNF1B, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, SPINK1, TP53, WRN and WT1.

A genetic contribution to prostate cancer risk has been documented, and knowledge about the molecular genetics of the disease is increasing. Genetic involvement in prostate cancer includes the following suggestive factors: 1) multiple first-degree relatives with prostate cancer, 2) including three successive generations with prostate cancer in the maternal and paternal lines; 3) early-age onset prostate cancer and 4) prostate cancer with a family history of other cancers (breast, ovarian, pancreatic). Additional factors include smoking, obesity, vasectomy, chemical exposure, obesity, STDs, alcohol use, increasing age and African-American ethnicity.